iX Biopharma Ltd.

(Company Registration No. 200405621W)

UNAUDITED FINANCIAL STATEMENTS FOR THE SECOND HALF AND FULL FINANCIAL YEAR ENDED 30 JUNE 2020

1(a)(i) A statement of comprehensive income, for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Group 6 months ended			Group 12 months ended		
	30.06.20 S$'000	30.06.19 S$'000	Incr/(Decr) %	30.06.20 S$'000	30.06.19 S$'000	Incr/(Decr) %
Continuing Operations						
Revenue	691	463	49%	985	671	47%
Cost of sales	(883)	(848)	4%	(1,572)	(1,200)	31%
Gross Loss	**(192)**	**(385)**	(50%)	**(587)**	**(529)**	11%
Other income	609	176	246%	1,047	759	38%
Expenses						
- Research and development	(1,262)	(1,412)	(11%)	(2,499)	(3,765)	(34%)
- Sales and marketing	(1,068)	(1,009)	6%	(2,260)	(2,024)	12%
- General and administrative	(3,255)	(2,980)	9%	(6,346)	(5,821)	9%
- Others †	552	(607)	n.m.	384	(1,656)	n.m.
- Finance expense	(118)	(111)	66%	(238)	(232)	33%
Total expenses	(5,151)	(6,119)	(16%)	(10,959)	(13,498)	(19%)
Loss from continuing operations before income tax	(4,734)	(6,328)	(25%)	(10,499)	(13,268)	(21%)
Income tax credit	-	5	n.m.	-	22	n.m
Loss from continuing operations	**(4,734)**	**(6,323)**	(25%)	**(10,499)**	**(13,246)**	(21%)
Discontinued Operation						
Loss from operation, net of tax	-	(174)	n.m.	-	(94)	n.m.
Gain on disposal of subsidiary	-	10,349	n.m.	-	10,349	n.m.
Profit from discontinued operation	-	10,175	n.m.	-	10,255	n.m.
Total (loss)/profit	**(4,734)**	**3,852**	n.m.	**(10,499)**	**(2,991)**	251%
Other comprehensive income:						
Items that may be reclassified subsequently to profit or loss:						
Currency translation differences arising from consolidation						
- (Loss)/gain	(469)	699	n.m.	(370)	1,447	n.m.
- Reclassification on disposal of subsidiary	-	(185)		-	(185)	n.m.
Other comprehensive (loss)/ income, net of tax	(469)	514	n.m.	-	1,262	n.m.
Total comprehensive loss	**(5,203)**	**4,366**	n.m.	**(10,869)**	**(1,729)**	529%

Note

† *Comprises net currency exchange (losses) / gains principally due to unrealised translation differences arising from foreign currency deposits and the receivables from subsidiaries.*

n.m. : not meaningful
Incr/(Decr) : Increase / (Decrease)

1(a)(ii) The following items (with appropriate breakdowns and explanations), if significant, must either be included in the income statement or in the notes to the income statement for the current financial period reported on and the corresponding period of the immediately preceding financial year:

Total loss of the Group is arrived at after charging/crediting the following:

		Group			Group		
		6 months ended			12 months ended		
	Note	30.06.20 S$'000	30.06.19 S$'000	Incr/ (Decr) %	30.06.20 S$'000	30.06.19 S$'000	Incr/ (Decr) %
After crediting:							
Research and development tax incentive	(i)	188	(68)	n.m.	405	208	95%
Interest income		22	83	(74%)	87	194	(55%)
Gain on disposal of subsidiary		-	10,349	n.m.	-	10,349	n.m.
After charging:							
Share-based payment expense	(ii)	254	347	(27%)	538	708	(24%)
Depreciation and amortisation expense							
- Property, plant and equipment		331	471	30%	671	1,216	(45%)
- Right of use assets		198	-	n.m.	378	-	n.m
Inventory write-down		56	19	195%	56	19	195%
Currency exchange (gains)/losses - net		(552)	607	n.m.	(384)	1,656	n.m.
Interest expense		118	117	(1%)	238	249	(4%)

(i) The research and development (R&D) tax incentive is a programme administered jointly by the Australian Taxation Office and Innovation Australia which provides a rate of 43.5% refundable tax offset for expenditure incurred for eligible R&D activities. (See Note 8 for details)

(ii) The share-based payment expense was due to amortisation of the fair value of the share options granted to employees over the vesting period.

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

	Group		Company	
	30.06.20 S$'000	30.06.19 S$'000	30.06.20 S$'000	30.06.19 S$'000
ASSETS				
Current assets				
Cash and cash equivalents	5,663	15,872	3,593	14,308
Trade and other receivables	1,300	1,425	15,816	10,871
Other current assets	297	362	206	171
Inventories	883	850	-	-
	8,143	18,509	19,615	25,350
Non-current assets				
Deposits – operating lease	105	81	-	81
Intangible assets	447	460	108	102
Property, plant and equipment	8,026	7,636	189	256
Right of use assets	261	-	230	-
Investments in subsidiaries	-	-	1,966	1,966
	8,839	8,177	2,493	2,405
Total assets	16,982	26,686	22,108	27,755
LIABILITIES				
Current liabilities				
Trade and other payables	2,824	2,310	1,709	1,149
Borrowings	216	211	25	23
Lease liabilities	245	-	226	-
Provision	12	10	-	-
	3,297	2,531	1,960	1,172
Non-current liabilities				
Provision	60	36	-	-
Borrowings	3,438	3,620	55	80
Lease liabilities	19	-	6	-
	3,517	3,656	61	80
Total liabilities	6,814	6,187	2,021	1,252
NET ASSETS	10,168	20,499	20,087	26,503
EQUITY				
Capital and reserves attributable to equity holders of the Company				
Share capital	72,251	71,525	72,251	71,525
Other reserves	1,653	2,211	320	508
Accumulated losses	(63,736)	(53,237)	(52,484)	(45,530)
Total equity	10,168	20,499	20,087	26,503

1(b)(ii) In relation to the aggregate amount of the group's borrowings and debt securities, specify the following as at the end of the current financial period reported on with comparative figures as at the end of the immediately preceding financial year.

	30.06.20			30.06.19		
	Unsecured	Secured	Total	Unsecured	Secured	Total
Amount repayable in one year or less	245	216	461	-	211	211
Amount repayable after one year	19	3,438	3,457	-	3,620	3,620
Total	**264**	**3,654**	**3,918**	**-**	**3,831**	**3,831**

Unsecured loans are lease liabilities recognised under SFRS(I) 16. Secured loans are bank borrowings and secured over land and building, certain plant and equipment, motor vehicles and certain bank deposits of subsidiaries of the Group

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Group 6 months ended		Group 12 months ended	
	30.06.20 S$'000	**30.06.19 S$'000**	**30.06.20 S$'000**	**30.06.19 S$'000**
Cash flows from operating activities				
Total (loss)/profit after tax	(4,734)	3,852	(10,499)	(2,991)
Adjustments for:				
- Deferred government grant income	-	(8)	-	(16)
- Depreciation and amortisation expense	529	471	1,049	1,216
- Gain on disposal of subsidiary	-	(10,349)	-	(10,349)
- Income tax expenses/(credit)	-	15	-	(44)
- Interest income	(22)	(83)	(87)	(194)
- Interest expense	118	117	238	249
- Provision	15	67	24	67
- Research and development tax incentive	(188)	68	(405)	(208)
- Share based payment expense	254	347	538	708
- Inventory write-down	56	19	56	19
- Loss on disposal of property, plant and equipment	1	-	1	-
- Unrealised currency exchange (gains)/losses – net	(529)	533	(324)	1,343
	(4,500)	(4,951)	(9,409)	(10,200)
Changes in working capital:				
- Trade and other receivables	(248)	210	(230)	(31)
- Other current assets	(95)	(220)	67	(68)
- Trade and other payables	780	(851)	504	(3,422)
- Inventories	(80)	(87)	(81)	(369)
Cash used in operations	(4,143)	(5,899)	(9,149)	(14,090)
Interest received	38	68	87	189
Research and development tax incentive received	-	-	742	-
Net cash used in operating activities	(4,105)	(5,831)	(8,320)	(13,901)
Cash flows from investing activities				
Additions to property, plant and equipment	(584)	(198)	(984)	(1,534)
Disposal of a subsidiary, net of cash disposed of	-	11,432	-	11,432
Additions to intangible assets	(1)	(154)	(10)	(154)
Net cash (used in)/from investing activities	(585)	11,080	(994)	9,744
Cash flows from financing activities				
Increase in fixed deposits pledged	-	(1,163)	-	(763)
Repayment of borrowings	(109)	(415)	(213)	(565)
Principal payment of lease liabilities	(197)	-	(375)	-
Proceeds from borrowings	-	-	-	-
Interest paid	(118)	(117)	(238)	(249)
Net cash used in financing activities	(424)	(1,695)	(826)	(1,577)
Net (decrease)/increase in cash and cash equivalents	(5,114)	3,554	(10,140)	(5,734)
Cash and cash equivalents				
Beginning of financial period	9,623	11,363	14,709	20,666
Effects of currency translation on cash and cash equivalents	(39)	(208)	(99)	(223)
End of financial period	4,470	14,709	4,470	14,709

Note:

A. Cash and cash equivalents comprise the following:

	Group 30.6.20 S$'000	**Group 30.6.19 S$'000**
Cash and cash equivalents in Balance Sheet	5,663	15,872
Less: Bank deposits pledged	(1,193)	(1,163)
Cash and cash equivalents per consolidated statement of cash flows	4,470	14,709

Bank deposits are pledged as security for credit facilities.

B. The Group purchased property, plant and equipment with an aggregate cost of $1.66 million during FY2019. Of the total purchase, $0.12 million was acquired under finance lease arrangement.

C. Reconciliation of liabilities arising from financing activities

	1 Jul 2019	Principal and interest payments	Non-cash changes: Adoption of SFRS(I) 16	Non-cash changes: Interest expense	Non-cash changes: Foreign exchange movement	30 June 2020
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
Bank borrowings	3,831	(425)	-	213	35	3,654
Lease liabilities	-	(401)	639	25	1	264

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Attributable to equity holders of the Company				
Group	**Share capital**	**Share based payment reserve**	**Currency translation reserve**	**Accumulated losses**	**Total equity**
	S$'000	S$'000	S$'000	S$'000	S$'000
At 1 July 2019	71,525	508	1,703	(53,237)	20,499
Loss for the period	-	-	-	(5,765)	(5,765)
Other comprehensive gain for the period	-	-	99	-	873
Total comprehensive gain/(loss) for the period	-	-	99	(5,765)	(5,666)
Share based payment scheme					
- Value of employees' services	-	284	-	-	284
- Shares issued pursuant to iX Performance Share Plan	726	(726)	-	-	-
Total transactions with owners, recognised directly in equity	726	(442)	-	-	284
At 31 December 2019	**72,251**	**66**	**1,802**	**(59,002)**	**15,117**
Loss for the period	-	-	-	(4,734)	(4,734)
Other comprehensive loss for the period	-	-	(469)	-	(469)
Total comprehensive loss for the period	-	-	(469)	(4,734)	(5,203)
Share based payment scheme					
- Value of employees' services	-	254	-	-	254
- Shares issued pursuant to iX Performance Share Plan	-	-	-	-	-
Total transactions with owners, recognised directly in equity	-	254	-	-	254
At 30 June 2020	**72,251**	**320**	**1,333**	**(63,736)**	**10,168**
At 1 July 2018	71,129	196	441	(50,246)	21,520
Loss for the period	-	-	-	(6,843)	(6,843)
Other comprehensive gain for the period	-	-	748	-	748
Total comprehensive gain/(loss) for the period	-	-	748	(6,843)	(6,095)
Share based payment scheme					
- Value of employees' services	-	361	-	-	361
- Shares issued pursuant to iX Performance Share Plan	396	(396)	-	-	-
Total transactions with owners, recognised directly in equity	396	(35)	-	-	361
At 31 December 2018	**71,525**	**161**	**1,189**	**(57,089)**	**15,786**

Group	Attributable to equity holders of the Company				
	Share capital	Share based payment reserve	Currency translation reserve	Accumulated losses	Total equity
	S$'000	S$'000	S$'000	S$'000	S$'000
At 31 December 2018	**71,525**	**161**	**1,189**	**(57,089)**	**15,786**
Profit for the period	-	-	-	3,852	3,852
Other comprehensive gain for the period	-	-	514	-	514
Total comprehensive gain for the period	-	-	514	3,852	4,366
Share based payment scheme - Value of employees' services	-	347	-	-	347
Total transactions with owners, recognised directly in equity	-	347	-	-	347
At 30 June 2019	**71,525**	**508**	**1,703**	**(53,237)**	**20,499**

Company	Attributable to equity holders of the Company			
	Share capital	Share based payment reserve	Accumulated losses	Total equity
	S$'000	S$'000	S$'000	S$'000
At 1 July 2019	71,525	508	(45,530)	26,503
Loss for the period	-	-	(3,655)	(3,655)
Total comprehensive loss for the period	-	-	(3,655)	(3,655)
Share based payment scheme				
- Value of employees' services	-	284	-	284
- Shares issued pursuant to iX Performance Share Plan	726	(726)	-	-
Total transactions with owners, recognised directly in equity	726	(442)	-	284
At 31 December 2019	**72,251**	**66**	**(49,185)**	**23,132**
Loss for the period	-	-	(3,299)	(3,299)
Total comprehensive loss for the period	-	-	(3,299)	(3.299)
Share based payment scheme				
- Value of employees' services		254		254
- Shares issued pursuant to iX Performance Share Plan	-	-	-	-
Total transactions with owners, recognised directly in equity	-	254	-	254
At 30 June 2020	**72,251**	**320**	**(52,484)**	**20,087**
At 1 July 2018	71,129	196	(42,808)	28,517
Loss for the period	-	-	(5,800)	(5,800)
Total comprehensive loss for the period	-	-	(5,800)	(5,800)
Share based payment scheme				
- Value of employees' services	-	361	-	361
- Shares issued pursuant to iX Performance Share Plan	396	(396)	-	-
Total transactions with owners, recognised directly in equity	396	(35)	-	361
At 31 December 2018	**71,525**	**161**	**(48,608)**	**23,078**
Profit for the period	-	-	3,078	3,078
Total comprehensive gain for the period	-	-	3,078	3,078
Share based payment scheme				
- Value of employees' services	-	347	-	347
Total transactions with owners, recognised directly in equity	-	347	-	347
At 30 June 2019	**71,525**	**508**	**(45,530)**	**26,503**

Save for the foregoing, there are no (i) changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders.

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

Company	6 months ended 30.06.20		12 months ended 30.06.20	
	No. of ordinary shares	Amount	No. of ordinary shares	Amount
		S$'000		S$'000
At beginning of period	648,894,390	72,251	644,594,057	71,525
Shares issued pursuant to iX Performance Share Plan	-	-	4,300,333	726
At end of period	**648,894,390**	**72,251**	**648,894,390**	**72,251**

On 15 November 2019, the Company announced total awards of 2,717,333 shares to certain employees and executives under iX Performance Share Plan. No award was granted to a Director or controlling shareholder (and each of their associates). The Company has not granted any options under iX Employee Share Option Scheme since its inception.

On same day, the Company issued 4,300,333 ordinary shares pursuant to iX Performance Share Plan. No share was issued to a Director or controlling shareholder (and each of their associates).

Save as disclosed, there are no other changes in the Company's share capital arising from any rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous reported period.

	Number of outstanding share awards / share options	Number of Shares that may be issued upon exercise of options / release of awards
As at 30 June 2020		
iX Performance Share Plan	2,384,000	2,384,000
As at 30 June 2019		
iX Performance Share Plan	4,100,000	4,100,000

There were no treasury shares and subsidiary holdings as at 30 June 2020 and 30 June 2019.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

As at 30 June 2020, the number of issued shares excluding treasury shares was 648,894,390 (30 June 2019: 644,594,057).

1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

Not applicable. There were no treasury shares during and as at the end of the current financial period reported on.

1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable. There were no subsidiary holdings during and as at the end of the current financial period reported on.

2. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The figures have not been audited nor reviewed by the Company's auditor.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications modifications or emphasis of a matter).

Not applicable.

3A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:
(a) Updates on the efforts taken to resolve each outstanding audit issue.
(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.
This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

Except as disclosed in paragraph 5 below, the Group has applied the same accounting policies and methods of computation in the financial statements for the current financial period compared with those of the audited financial statements as at 30 June 2019.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

On 1 July 2019, the Group adopted the standards, amendments and interpretations to existing standards that are mandatory for application from that date. The new SFRS(I) that is relevant to the Group:

SFRS(I) 16 Leases
SFRS(I) 16 will result in almost all leases being recognised on the balance sheet, as the distinction between operating and finance leases is removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognised. The only exceptions are short-term and low-value leases. The accounting for lessors will not change significantly.

The Group applied the standard from its mandatory adoption date of 1 July 2019. The Group applied the simplified transition approach and has not restated comparative amounts for the year prior to first adoption. Right-of-use assets were measured at the amount of the lease liability on adoption (adjusted for any prepaid or accrued lease expenses).

As a result of initially applying SFRS(I) 16, in relation to the leases that were previously classified as operating leases, the Group recognised right-of-use assets of $639,000 and lease liabilities of $639,000 as at 1 July 2019.

In relation to those leases under SFRS(I) 16, the Group has recognised depreciation and interest costs, instead of operating lease expenses. During FY2020, the group recognised depreciation charge of $377,000 and interest expense of $25,000 from these leases.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends:
(a) based on the weighted average number of ordinary shares on issue; and
(b) on a fully diluted basis (detailing any adjustments made to the earnings).

	Group 6 months ended		Group 12 months ended	
	30.06.20	30.06.19	30.06.20	30.06.19
Net (loss)/profit attributable to equity holders of the Company (S$'000)				
- Continuing operations	(4,734)	(6,323)	(10,499)	(13,246)
- Discontinued operation	-	10,175	-	10,255
Weighted average number of shares outstanding ('000)				
- Basic	648,894	644,594	647,285	643,830
- Diluted	648,894	648,694	647,285	646,942
Basic (loss)/profit per share (Cents per share)				
- Continuing operations	(0.73)	(0.98)	(1.62)	(2.06)
- Discontinued operation	-	1.58	-	1.59
Diluted (loss)/profit per share (Cents per share)				
- Continuing operations	(0.73)	(0.97)	(1.62)	(2.05)
- Discontinued operation	-	1.57	-	1.59

The Company has 2,384,000 share awards under iX Performance Share Plan (30 June 2019: 4,100,000 shares awards) which could potentially dilute basic earnings per share in the future but were not included in the calculation of diluted loss per share for continuing operations above because they are antidilutive and having the effect of decreasing the loss per share.

7. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:
(a) current financial period reported on; and
(b) immediately preceding financial year.

	Group		Company	
	30.06.20	30.06.19	30.06.20	30.06.19
Net asset value per ordinary share (in cents)	1.6	3.2	3.1	4.1

The net asset value per ordinary share of the Group and the Company as at 30 June 2020 were calculated based on the total number of issued shares of 648,894,390 (30 June 2019: 644,594,057).

There were no treasury shares as at 30 June 2020 and 30 June 2019.

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:

(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and

(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

Overview

The Group is a specialty pharmaceutical company focused on the development and commercialisation of innovative therapies for improving the quality of life of those suffering from pain and other health conditions. The Company leverages its drug formulation expertise and patented sublingual drug delivery technology, **WaferiX**, to develop products for rapid onset of action with potentially more predictable effects and ease of use. The Group's nutraceuticals division, Entity Health, is engaged in the development and commercialisation of nutraceutical products that address specific health conditions and improve quality of lifestyles throughout all phases of life.

During the half year ended 30 June 2020 (2H20), the Group has continued to progress the development of its pharmaceutical and nutraceutical product pipeline.

Wafermine

Wafermine is the world's first sublingual ketamine to be developed for moderate to severe acute pain. The programme reached an important milestone during financial year ended 30 June 2020 (FY2020) with the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (US FDA). During the meeting, the Company and the US FDA reached agreement on key aspects of the pivotal Phase 3 clinical trial programme to support approval of Wafermine for the indication of acute moderate to severe pain.

The Phase 3 programme will consist of two randomised, double blind, placebo-controlled studies, one in an orthopaedic pain model (bunionectomy) and one in a soft-tissue pain model (abdominoplasty). Both post-operative pain models were successfully evaluated in the recent Phase 2b clinical study which gives us great confidence that the results can be replicated in Phase 3. The primary efficacy measure for both studies will be SPID12, which is the summed pain intensity difference over 12 hours. The summed pain intensity difference over 24 hours (SPID24) and 48 hours (SPID48) will be evaluated as secondary endpoints.

Importantly, confirmation of the EOP2 meeting with the US FDA gives clarity to the Wafermine development program, especially costs and timeline of Phase 3 studies. Further, it positions the Company well to continue out-licensing discussions with potential licensees.

In addition to the treatment of pain, Wafermine is Phase 2-ready for major depressive disorder (MDD). In recent decades, racemic ketamine has also proven to be effective for treatment-resistant depression (TRD).

Wafermine is currently supplied to hospitals in Australia under Schedule 5A of the Therapeutic Goods Regulations (TGR) as an unregistered medicine, with approximately 300,000 wafers sold to-date.

Xativa and Medicinal Cannabis

In April 2020, the Group launched Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer. Xativa is available as an unregistered medicine by doctors' prescription under the Special Access Scheme and Authorised Prescriber pathway in Australia. Xativa, which contains a nano-emulsion of broad-spectrum CBD (cannabidiol) and delivered using the Group's patented WaferiX sublingual delivery technology, is a highly differentiated and superior dosage form that improves bioavailability of CBD, providing patients with rapid absorption, faster therapeutic action and predictable outcome.

CBD, one of the primary non-psychoactive compounds found in the cannabis plant, has attracted growing interest in recent times due to its safety and effectiveness in treating a vast spectrum of human health issues. While its medicinal benefits are clear, most delivery forms available today suffer from the lack of fixed unit dosages, inconsistent absorption and variable or poor bioavailability

to truly provide an effective therapeutic effect for users. Leveraging on WaferiX technology, the Group has developed Xativa™ to address this gap in the market.

Xativa currently comes in a 12.5mg CBD dose strength, with a 25mg dose scheduled for launch in the quarter ending 30 September 2020. Xativa is currently prescribed by doctors for a wide variety of conditions including treating anxiety, relieving pain, reducing inflammation, and improving sleep quality, among other conditions, to patients who are not effectively treated with other drugs.

Xativa is distributed in Australia through both wholesale distribution channels and directly to retail pharmacies. The Group regularly conducts doctor education and product training to familiarise them with Xativa and our WaferiX technology. The response since launch from both prescribers and patients has been exceptional and is in recognition of the enhanced clinical utility that this novel dosage form offers. Initial production runs totalling approximately 1,700 boxes of Xativa have been fully sold.

Wafesil and Silcap

The Group obtained marketing approval from the TGA in Australia for Wafesil and Silcap, both for the treatment of male erectile dysfunction. Wafesil and Silcap are available in dosage strengths of 25 mg and 50 mg in pack sizes of 4, 8 and 12 wafers and capsules, respectively.

In April 2020, the Group announced its first pharmaceutical licensing transaction for Wafesil with Yiling Pharmaceutical Ltd (Yiling) in China. Under the terms of the licensing agreement, Yiling will be the exclusive distribution partner for Wafesil in China upon registration of the drug with the Chinese regulatory authorities. Yiling has paid an upfront fee to the Company and will pay milestone fees upon the completion of bioequivalence studies and on the first commercial supply of wafers by the Group to Yiling. In addition, Yiling has agreed to fund bioequivalence studies and will bear the cost of regulatory submissions for registration in China, a process which is expected to take around 24 months. By partnering with Yiling, the Group will be able to access the market through Yiling's sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China. The Group will manufacture and supply Wafesil to Yiling at an agreed supply price.

During 2H20, the Group commenced the supply of Wafesil & Silcap in Australia through telemedicine. Telemedicine, where doctors prescribe medication after holding online consultations with patients on digital platforms, enables patients to access medical advice and treatment safely, discreetly and conveniently. Telemedicine has recorded rapid adoption amid the Covid-19 pandemic as patients turn to digital health technologies and platforms for medical care.

The Company has applied for registration of Wafesil in Europe with the European Medicines Agency (EMA) and the application is currently under evaluation. Silcap has also been filed for registration with the Health Sciences Authority in Singapore and is currently under evaluation.

BnoX

BnoX is a novel, sublingual buprenorphine wafer developed for the management of acute and chronic moderate to severe pain. Despite the current opioid crisis, there has been a continuing reliance on opioids to treat moderate to severe pain due to a lack of effective alternatives. As a consequence, there has been increasing recognition and focus on opioids which have a far favourable safety profile, such as buprenorphine.

BnoX is currently being supplied to hospitals in Australia under Schedule 5A of the TGR as an unregistered medicine.

Nutraceuticals – Entity Health

Entity nutraceuticals, unlike generic vitamins and minerals, are designed to produce beneficial and perceptible improvement to specific conditions and form an important part of a healthcare strategy to prevent more serious diseases. Since its market introduction in 1Q19, Entity had focused its sales and marketing activities to build its presence in Australia. Due to robust Australian TGA regulations, Australian health supplement brands are regarded as the gold standard of healthcare products not only in the country but also by Chinese consumers. To-date, Entity nutraceuticals are stocked in more than 250 pharmacies and health food shops across major cities in Australia.

Having established brand awareness and credibility as a quality brand in Australia, we turned our attention to the China market. In April 2020, we launched our flagship Entity stores on Tmall Global and JD Worldwide, two of the largest cross-border e-commerce platforms in China commanding over 85% of the total B2C e-commerce market in China. The full range of 11 Entity products are sold on the stores. During the store launch period, the stock of LumeniX and RestoriX sold out on the stores within 3 weeks of launch. LumeniX is a sublingual glutathione beauty product formulated using the WaferiX delivery technology for skin fairness and to boost immune system functions as a master-antioxidant and RestoriX is a nicotinamide supplement designed to boost NAD+ (nicotinamide adenine dinucleotide) levels in the body. NAD+ is a molecule that has been studied in recent years for its ability to switch off 'ageing' genes. RestoriX aims to counter the process of ageing and increase health span, while boosting energy levels and vitality.

Since then we have continued to see strong demand and uptake for our products, particularly products in the NAD+ and skin care category. During the annual 618 online shopping event in June, approximately 1,500 bottles of NAD supplements and 500 boxes of LumeniX that were allocated for the sale were sold out on Tmall Global and JD Worldwide.

In 2H20, we expanded our product range in Australia to nine products, including the introduction of MomoriX into the market. MomoriX is a natural plant-based supplement optimised to support healthy blood glucose levels.

Review of performance for half year (2H20) and full year (FY2020) ended 30 June 2020

Continuing Operations

Continuing Operations comprise of the Group's specialty pharmaceutical and nutraceutical businesses.

Revenue	2H20	2H19	Incr/ (Decr)	FY2020	FY2019	Incr/ (Decr)
	S$'000	S$'000	%	S$'000	S$'000	%
Specialty Pharmaceutical	432	343	26%	593	393	51%
Nutraceuticals	259	120	116%	392	278	41%
Total revenue	**691**	**463**	**49%**	**985**	**671**	**47%**

Revenue increased by 49% and 47% in 2H20 and FY2020 respectively. Notably, during the fourth quarter of the year (4Q20), the Group recorded S$0.56 million in revenue, representing 81% and 57% of the total revenue in 2H20 and FY2020 respectively.

Xativa's launch, telemedicine sales and licensing of Wafesil contributed to these increases in the Specialty Pharmaceuticals revenue in 2H20 and FY2020.

Nutraceutical division Entity Health recorded $0.20 million in 4Q20 or 77% and 50% of revenue in 2H20 and FY2020 respectively, contributed mainly by its flagship stores on Tmall Global & JD Worldwide launched in 4Q20. Its revenue grew by 116% and 41% in 2H20 and FY2020 over the comparable periods in FY2019. LumeniX, RestoriX and LiviUp were the best sellers across China and Australia.

The Group's cost of sales was S$0.88 million in 2H20 as compared to S$0.85 million in 2H19. In FY2020, cost of sales was S$1.57 million as compared to S$1.20 million in FY2019. The cost of sales also includes the cost of manufacturing which consists of personnel, material and other fixed overheads.

The Group lowered its gross loss in 2H20 as compared to 2H19 mainly due to higher revenue and favourable mix of higher margin products. A marginally larger gross loss was recorded for FY2020 as compared to FY2019 as the Group has yet to achieve a level of sales to benefit from economies of scale in the earlier quarters of FY2020.

Other income - Research and Development (R&D) Incentive

The Group conducts its R&D activities through its wholly owned subsidiaries in Australia and has been eligible for R&D tax incentive under a programme administered jointly by the Australian Taxation Office and Innovation Australia. This incentive provides a rate of 43.5% tax rebate for

eligible R&D expenditure incurred in Australia by these subsidiaries. During 2H19, the Group recorded a net reversal arising from its review and revision of its estimate of the related incentive previously accrued. The revision also led to lower R&D incentives being recognised for FY2019.

Expenses

During FY2020, the Group's operating expenses, excluding net currency exchange differences and certain one-off regulatory and registration expenses, were reduced by 8.5% as compared to FY2019.

The expense items in loss before tax were analysed below:

R&D expense

During the periods, R&D activities were focused on new product development for our medicinal cannabis range, nutraceuticals and pharmaceuticals as well as enhancements to certain products. In FY2019, R&D expenses were higher due to certain KET010 clinical trial related expenses.

Sales and marketing

Sales and marketing expenses during the year were $2.26 million as compared to S$2.02 million in FY2019. We focused our sales and marketing efforts on activities with higher returns resulting in a modest increase of 12% in expenses in return for much larger 47% increase in sales.

General and administrative (G&A)

As more of our products are commercialised, we have incurred additional regulatory and compliance related expenses. These included one-off expenses totalling S$0.53 million incurred in relation to the Wafermine EOP2 meeting with US FDA in September 2019 and registration of Wafesil in Europe in January 2020.

As part of our strategy to monetise our assets, we have engaged a financial advisor to assist in out-licensing Wafermine.

We have reduced travelling and personnel related costs in part due to COVID-19 and cost rationalisation. Except for the increases due to regulatory activities and engagement of advisors, G&A expense for FY2020 was comparable to that for FY2019.

Others

Others consist solely of currency exchange gain/loss.

During FY2020 we observed another volatile environment in currency exchanges, particularly in Australian and US dollars. The depreciation of the Australian dollar against the Singapore dollar during most of FY2020 impacted our cash holding and the receivables from our subsidiaries. Late recovery of Australian dollar against the Singapore dollar in 4Q20 led to a small gain of S$0.38 million this financial year as compared to a loss of S$1.66 million in FY2019.

Discontinued Operation

Discontinued operation comprised the laboratory testing business disposed of in 3Q19.

Review of financial position

Current assets of the Group decreased to S$8.15 million from S$18.51 million, principally in our cash and cash equivalents. The decrease was mainly due to cash outflow from operating activities and the purchase of manufacturing equipment.

On adoption of SFRS(I) 16 Leases on 1 July 2019, the Group recognised the right of use assets of S$0.64 million arising from recognition of leases previously classified as operating leases and offset by depreciation of $0.38 million. Correspondingly, lease liabilities of S$0.64 million were recognised and offset by lease payments during the year.

Current liabilities of the Group increased to S$3.31 million from S$ $2.53 million. The increase was mainly due to deferred submission fee for registration of Wafesil in Europe and current portion of lease liabilities recognised in accordance with SFRS(I) 16.

During the year, we repaid some S$0.18 million of borrowings thus reducing our total borrowings to S$3.65 million from S$3.83 million. We successfully extended revolving credit and property loan

facilities totalling A$5.00 million that would be expiring at the end of FY2021 for a further two years. As at the balance sheet date, available revolving credit was A$1.27 million.

Cash flow analysis

The Group recorded lower net cash used in operating activities of S$4.11 million during 2H20 (2H19: S$5.83 million) and $8.34 million during FY2020 (FY2019: S$13.90 million). These were mainly due to improved sales in 2H20 while for FY2019, higher cash was used in the discontinued operations prior to disposal, KET010 clinical trial payments and rental payments (which are now reported as repayment of lease liabilities).

The Group paid S$0.58 million and S$1.00 million in 2H20 and FY2020 respectively, principally for freeze drying related equipment.

During 2H19, the Group received S$11.43 million cash proceeds from the disposal of laboratory testing business. At the same time, the Group also restructured its bank credit facilities in Australia by providing A$1.23 million (S$1.16 million) in fixed bank deposits as collaterals.

During FY2019, net cash used in financing activities was S$1,5 million due to repayment of borrowings and interest of 0.81 million and an additional S$0.76 million in fixed bank deposits being provided to a bank as collateral.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable. No forecast or prospect statement had been previously disclosed to shareholders for the current reporting period.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Wafermine

During a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (US FDA), the Company and the US FDA reached agreement on key aspects of the pivotal Phase 3 clinical trial programme to support approval of Wafermine for the indication of acute moderate to severe pain. With clarity on the Phase 3 development programme and the recent allowance of our US patent for Wafermine this year, we now have all the critical elements to out-license Wafermine to a suitable third party. We have engaged a financial and strategic adviser to guide the out-licensing activities for Wafermine.

Out-licensing Wafermine is a strategy that will allow us to fully unlock the value of the drug. A suitable partner will enable the Company to tap into its resources to fund, and expertise to run and complete, Phase 3 clinical development and obtain marketing approval for Wafermine. The Group can then access markets through its partners' infrastructure and sales networks to manage the commercialisation of the product more effectively.

Xativa & Medicinal Cannabis

In April 2020, we launched Xativa, a sublingual medicinal cannabis wafer containing CBD (cannabidiol) in Australia. Xativa is available as an unregistered medicine by doctors' prescription under Special Access Scheme and Authorised Prescriber pathway in Australia. We distribute Xativa via cannabis distributors such as Cannatrek Ltd or directly to pharmacies.

Xativa, which contains a nano-emulsion of broad-spectrum CBD (cannabidiol) and delivered using the Group's patented WaferiX sublingual delivery technology, is a highly differentiated and superior dosage form that improves bioavailability of CBD, providing patients with rapid absorption, faster therapeutic action and predictable outcome.

CBD, one of the primary non-psychoactive compounds found in the cannabis plant, has attracted growing interest in recent times due to its safety and effectiveness in treating a vast spectrum of human health issues. While its medicinal benefits are clear, most delivery forms available today

suffer from the lack of fixed unit dosages, inconsistent absorption and variable or poor bioavailability to truly provide an effective therapeutic effect for users. Leveraging on WaferiX technology, the Group has developed Xativa™ to address this gap in the market.

According to analysts, the legal medicinal cannabis market in Australia and New Zealand will be valued at US$1.55 billion in 2024[1]. In Australia, prescription numbers have risen rapidly with over 18,500 medicinal cannabis patients as at 1 January 2020 and it is estimated that over 200,000[2] patients are eligible to use it. At the moment, 70% of the prescriptions are for pain-related conditions.

The Australian TGA has announced that it will consider rescheduling CBD as a Schedule 3 substance, which means that products in which CBD comprises 98% or more of the total cannabinoid content will be available over-the-counter without a prescription in pharmacies across Australia for therapeutic use. CBD is currently a Schedule 4 substance and therefore only available with a prescription. If the rescheduling is approved, registered CBD products will be more widely available in pharmacies and Australians will have greater and more convenient access to these products. It is expected that in that event, consumers will use CBD to address less serious conditions such as muscle recovery and to manage sleep, resulting in a greatly expanded market size.

The Group plans to introduce other medicinal cannabis products containing THC (tetrahydrocannabidiol) and CBD in various combinations to broaden the range and serve more patients. This will allow us to target and penetrate deeper, the entire addressable medicinal cannabis market.

Entity Health

Since the 2018 launch of Entity, the Group's nutraceuticals line, in Australia, we focused on penetrating the Australian market to establish Entity as a homegrown Australian health supplements brand. Australian-made health supplements are regarded by Chinese consumers as the gold standard of healthcare products due to Australia's reputation for safety and quality. Today, Entity products are sold in more than 250 pharmacies and health food stores in all major Australian cities.

In April 2020, we launched Entity flagship stores on JD Worldwide and Tmall Global. JD and Tmall are the two largest e-commerce platforms in China, commanding over 85% of the total B2C e-commerce market in China. Through these platforms, we are able to sell our nutraceutical products to the China consumers from Australia without lengthy and costly registration procedures to sell within the country. Chinese consumers now have access to the full range of 11 Entity nutraceuticals on the stores. The two bestselling products in the range are RestoriX, a nicotinamide supplement to boost NAD+ in the body for energy and vitality, and LumeniX, a sublingual glutathione wafer for skin fairness and to boost immune health systems as a powerful antioxidant.

Chinese consumers have demonstrated an appetite for novel and sophisticated products which characterise the Entity line of nutraceuticals. Within 3 weeks from commencement of sales into China, LumeniX and Restorix sold out on both stores. Since then we continued to see strong demand and uptake particularly of products in the skincare and anti-aging categories.

In the next 12 months we will prioritise growing the market share for Entity products in China through cross-border e-commerce. We intend to introduce new products in categories popular or growing with China consumers, focusing on leveraging our unique, patented WaferiX sublingual technology to produce well-differentiated and scientifically advanced products that resonate with Chinese consumers.

COVID-19

The Group's manufacturing facility and workforce remain operational during this period. Its offices and facility in Australia, Singapore and China have implemented a number of measures to protect the welfare of employees, and to prevent the spread of the virus within its regional office network. These include complying with all measures mandated by the governments of the countries that it operates in, such as staggered working hours, telecommuting arrangements and the limitation of

---

1 Prohibition Partners, 2020, "The Oceania Cannabis Report, Second Edition, April 2020"

2 NICM Health Research Institute, Western Sydney University, January 2020, "Submission to Senate Inquiry: Current Barriers to Patient Access to Medicinal Cannabis in Australia"

in-person meetings, when and where applicable. Protective face masks are provided to all staff daily for use in the workplace and during public transit to and from work, and there is a particular focus on personal hygiene measures, office sanitation and strict adherence to safe distancing measures within the workspaces.

Global travel and supply chains have been disrupted due to measures implemented by governments worldwide. Although the Group has observed cost increases and delays to services and deliveries with certain logistics partners, its business has not been significantly impacted. Despite the current global economic disruption, the Group has worked to secure new partnerships, launch new products and open new markets.

We have commenced out-licensing activities for Wafermine. Many biotech and pharmaceutical events and conferences which are the lifeblood of the pharmaceutical industry, essential to foster partnerships and collaborations between pharmaceutical companies, have been prohibited from taking place physically due to COVID-19 restrictions. Despite these challenges, we continue to engage with potential partners digitally.

The demand for sublingual wafer products, in particular LumeniX and Xativa, has exceeded the Group's current wafer production capacity. The Group has purchased new equipment which was scheduled to be commissioned in early 2020. However, due to the extended Australian border closure, the equipment supplier has been unable to send the technical staff required to perform the commissioning work. We now expect the production capacity upgrade to be completed in the quarter ending March 2021. This will increase wafer production capacity six-fold and enable the Group to address the growing demand for its wafer products following the opening of a new market for Entity nutraceutical products in China, and the launch of its medicinal cannabis drug in Australia.

Proposed Placement of 44,491,299 Shares

On 28 July 2020, the Company entered into a conditional subscription agreement to place out 44,491,299 shares in the Company to certain subscribers for a net proceed of approximately S$10.18 million to support the Group's development, manufacturing and marketing activities, as well as for general working capital.

The completion of the proposed placement is conditional upon, *inter alia*, the approval for allotment and issuance of the shares being obtained from the shareholders of the Company at an extraordinary general meeting to be convened on 4 September 2020 and listing quotation notice being obtained from SGX-ST.

The Company has made related announcements on 28 July and 11 August 2020 and will make further announcements as and when necessary, including upon completion of the proposed placement.

11. If a decision regarding dividend has been made:
(a) Whether an interim (final) ordinary dividend has been declared (recommended); and

No dividend has been declared or recommended for the current reporting period.

(b)(i) Amount per share (cents)

Not applicable.

(b)(ii) Previous corresponding period (cents)

Not applicable.

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).

Not applicable.

(d) The date the dividend is payable

Not applicable.

(e) Books closure date

Not applicable.

12. If no dividend has been declared (recommended), a statement to that effect.

No dividend has been declared or recommended for the current reporting period as the Company is in a loss position.

13. If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group does not have a general mandate for interested person transactions.

14. Use of Proceeds

(a) Initial Public Offer

Pursuant to the IPO, the Company received total proceeds of S$30.13 million (IPO Proceeds). As at 30 June 2020, the IPO Proceeds has been utilised as follows:

	Amount after re-allocation	Amount utilised	Balance
	S$'000	**S$'000**	**S$'000**
To fund the clinical trials for the development of our products, and for preparing and submitting an Abbreviated New Drug Application or New Drug Application as the case may be, to the US Food and Drug Administration for marketing approval and commercialisation of our products in the United States, and where it is commercially viable to do so, in other parts of the world upon receipt of the relevant regulatory approvals	15,286	(15,286)	-
To fund the development, manufacturing and marketing activities required for our pharmaceutical and nutraceutical products in the pipeline, including Wafermine, Wafesil (formerly PheoniX), Silcap (formerly XCalibur) and the Entity line of nutraceutical products	9,414	(9,414)	-
General working capital purposes	2,913	(2,913)	-
Listing expenses	2,517	(2,517)	-
Total	**30,130**	**(30,130)**	**-**

Details of working capital used:	**S$'000**
Professional fees	617
Payroll and directors' fees	1,596
Trademark and patents	67
Rental, office expenditure and other operating expenses	633
Total	**2,913**

The above utilisation of the Company's IPO Proceeds is in accordance with the intended use as stated in the Offer Document dated 10 July 2015 and as subsequently re-allocated by the Company in its announcement on 25 June 2018.

15. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the listing manual.

The Company has procured undertakings from all its Directors and executive officers under Rule 720(1).

PART II – ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT

16. Segmented revenue and results for operating segments (of the group) in the form presented in the issuer's most recently audited annual financial statements, with comparative information for the immediately preceding year.

(a) Business segments

The Group's business comprises of the Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical's primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical's primary business activities are the sale of nutraceutical products.

Group	Specialty Pharmaceutical	Nutraceutical	Total
FY2020	**S$000**	**S$000**	**S$000**
Total segment sales	787	389	1,176
Less:			
Inter-segment sales	(191)	-	(191)
Net sales to external parties	596	389	985
Adjusted EBITDA for reportable segments	(4,247)	(1,895)	(6,142)
Depreciation	593	-	593
Amortisation	25	-	25
FY2019			
Total segment sales	480	278	758
Less:			
Inter-segment sales	(87)	-	(87)
Net sales to external parties	393	278	671
Adjusted EBITDA for reportable segments	(4,956)	(1,854)	(6,810)
Depreciation	538	-	538
Amortisation	2	-	2

	FY2020 S$'000	FY2019 S$'000
Adjusted EBITDA is reconciled to loss before income tax as follows:		
Reportable segments	(6,142)	(6,810)
Unallocated corporate expenses	(3,408)	(3,641)
	(9,550)	(10,451)
Research and development tax incentive	405	208
Depreciation	(1,024)	(621)
Amortisation	(25)	(2)
Currency exchange losses - net	384	(1,656)
Share based payment expense	(538)	(708)
Finance expense	(238)	(232)
Interest income	87	194
Loss before income tax (continuing operations)	(10,499)	(13,268)

(b) Geographical segments

The Group's two business segments operate in three geographical areas.

	FY2020 S$'000	FY2019 S$'000
Net sales		
Singapore	50	88
China	308	-
Australia	627	583
	985	671
Non-current assets		
Singapore	526	439
Hong Kong	105	-
Australia	8,208	7,738
	8,839	8,177

17. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the operating segments.

Please refer to paragraph 8 for the analysis of revenue by operating segments.

An analysis of the Group's adjusted EBITDA by business segments consists of:

(1) the specialty pharmaceutical business with adjusted EBITDA loss of S$4.25 million as compared to loss of S$4.96 million in FY2019. The decrease was principally due to the timing and progress of clinical trials.

(2) the nutraceutical business with adjusted EBITDA loss of S$1.90 million as compared to loss of S$1.85 million in FY2019. The increase was mainly attributable to sales and marketing expenses to promote and commercialise its products.

18. A breakdown of net sales as follows:

	Group		
	FY2020	**FY2019**	**Incr / (Decr)**
	S$'000	**S$'000**	**%**
Net sales			
- First half year	294	208	41%
- Second half year	691	463	49%
Operating loss after tax			
- First half year	(5,765)	(6,923)	(17%)
- Second half year	(4,734)	(6,323)	(25%)

19. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year.

Not applicable. No dividends have been declared or recommended for the financial years ended 30 June 2020 and 30 June 2019.

20. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

Pursuant to Rule 704(10) of the Catalist Rules, there is no person occupying a managerial position in the Company or any of its principal subsidiaries who is related to a director or chief executive officer or substantial shareholder of the Company as at 30 June 2020.

On behalf of the Board of Directors

Eddy Lee Yip Hang
Chairman & CEO

Albert Ho Shing Tung
Non-executive Director

28 August 2020

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("Sponsor") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.